Challenges in Rotavirus Vaccine Efficacy in Low- and Middle-Income Countries
Rotavirus vaccine efficacy is significantly lower in low- and middle-income countries (45-65%) compared to high-income countries (85-90%).
Asset / Drug
Drug and asset intelligence for Challenges with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Vaccine
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.